Skip to main content
. 2022 May 23;25(9):720–726. doi: 10.1093/ijnp/pyac030

Table 1.

Basic Demographic, Physical, and Psychological Characteristics of the Study Sample (Means Plus SD in Parentheses)

Pramipexole
(n = 21; 10 male)
Placebo
(n = 19; 10 male)
Between-group comparison (t test)
Age 22.5 (3.7) 24.5 (6.9) P = .26
Body mass index 22.4 (2.6) 24.0 (2.9) P = .07
Years in full-time education 16.8 (2.9) 17.5 (3.1) P = .49
IQ estimate (Spot-the-Word Test) 108.3 (8.1) 111.9 (7.6) P = .16
Neuroticism (Eysenck Personality Questionnaire) 4.2 (3.7) 4.3 (3.7) P = .98
Psychoticism (Eysenck Personality Questionnaire) 2.5 (2.1) 2.8 (2.1) P = .64
Extraversion (Eysenck Personality Questionnaire) 14.7 (4.5) 14.5 (3.7) P = .89
Lie (Eysenck Personality Questionnaire) 9.5 (4.6) 7.5 (3.4) P = .12
Trait anxiety (State-Trait Anxiety Inventory) 31.2 (9.1) 32.1 (9.1) P = .77
Depression at inclusion (Beck Depression Inventory) 1.6 (1.7) 2.5 (4.0) P = .39

N.B.: Uneven distribution of pramipexole and placebo treatment due to random replacement of participant dropouts.